Funders · Entity Annotation Prototype (beta)

1articles mentioning funders

1funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: EMD Serono ×

EMD Serono

This funder is selected. Its supporting articles are shown below.

EMD Serono1

Articles mentioning EMD Serono

1 articles · page 1 of 1

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma

jitc · abstract · 2025-11-04 · 1 matching annotations

76.9%

Mark Foundation for Cancer Research EMD Serono tuvusertib ceralasertib durvalumab avelumab AZD6738

…ease. EDDOP Leadership Award-P30 Administrative Supplement, the Mark Foundation for Cancer Research, the Kelsey Dickson Team Science Courage Research Team Award, a…

Browse funders

EMD Serono

Articles mentioning EMD Serono

599 The MATRiX trial: a multicenter, randomized, phase II study of ATR inhibition (via tuvusertib) with or without avelumab in patients with advanced anti-PD-(L)1-refractory merkel cell carcinoma